We are live on ! Find out more
ATXS

Astria Therapeutics
ATXS

Delisted

ATXS was delisted on the 22nd of January, 2026.

Back to rankings

110 hedge funds and large institutions have $523M invested in Astria Therapeutics in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 42 increasing their positions, 24 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 24

47% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 17

7% more funds holding

Funds holding: 103 → 110 (+7)

3.6% more ownership

Funds ownership: 100.15% → 103.75% (+3.6%)

7% more call options, than puts

Call options by funds: $631K | Put options by funds: $591K

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16% less capital invested

Capital invested by funds: $622M → $523M (-$98.7M)

Holders
110
Holders Change
+7
Holders Change %
+6.8%
% of All Funds
1.45%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
25
Increased
42
Reduced
24
Closed
17
Calls
$631K
Puts
$591K
Net Calls
+$40K
Net Calls Change
+$327K

Top Buyers

Rank Fund Capital Flow
1
FIS
FCPM III Services
Netherlands
+$30.5M
2
UBS Group
UBS Group
Switzerland
+$13.9M
3
BlackRock
BlackRock
New York
+$4.22M
4
VPC
Vestal Point Capital
New York
+$1.91M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.5M

Top Sellers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
-$10.6M
2
AAA
Affinity Asset Advisors
New York
-$7.98M
3
Millennium Management
Millennium Management
New York
-$5.97M
4
Invesco
Invesco
Georgia
-$3.15M
5
State Street
State Street
Massachusetts
-$1.54M
Name Holding Trade Value Shares
Change 		Change in
Stake
Dimensional Fund Advisors
26
Dimensional Fund Advisors
Texas
$2.49M -$23.8K -2,241 -0.8%
Goldman Sachs
27
Goldman Sachs
New York
$1.94M -$587K -55,300 -20%
Morgan Stanley
28
Morgan Stanley
New York
$1.36M -$824K -77,555 -34%
Wellington Management Group
29
Wellington Management Group
Massachusetts
$1.32M +$5.84K +550 +0.4%
Walleye Capital
30
Walleye Capital
New York
$1.3M -$310K -29,179 -17%
SFM
31
Sphera Funds Management
Israel
$1.25M +$34.2K +3,218 +2%
UOC
32
UBS O'Connor
Illinois
$1.16M +$58K +5,464 +4%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$1.06M +$9.47K +892 +0.8%
PSC
34
Patient Square Capital
California
$939K +$697K +65,635 +166%
N
35
Nuveen
North Carolina
$925K – – –
TCM
36
Tang Capital Management
California
$894K – – –
Barclays
37
Barclays
United Kingdom
$875K +$54.9K +5,169 +6%
Bank of America
38
Bank of America
North Carolina
$820K +$108K +10,136 +12%
ACM
39
ADAR1 Capital Management
Texas
$813K -$24.4K -2,300 -2%
Raymond James Financial
40
Raymond James Financial
Florida
$707K +$840K +79,044 New
VOYA Investment Management
41
VOYA Investment Management
Georgia
$641K +$599K +56,366 +367%
Swiss National Bank
42
Swiss National Bank
Switzerland
$595K +$81.8K +7,700 +13%
UBS AM
43
UBS AM
Illinois
$567K +$82.4K +7,756 +14%
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$556K +$14.7K +1,381 +2%
JP Morgan Chase
45
JP Morgan Chase
New York
$489K +$165K +15,520 +40%
AllianceBernstein
46
AllianceBernstein
Tennessee
$483K – – –
Citigroup
47
Citigroup
New York
$483K +$212K +19,951 +59%
AA
48
ALPS Advisors
Colorado
$408K +$485K +45,630 New
American Century Companies
49
American Century Companies
Missouri
$382K +$40.8K +3,839 +10%
Deutsche Bank
50
Deutsche Bank
Germany
$355K +$149K +13,986 +54%
1
2
3 4 5

ATXS Hedge Fund Activity: Q4 2024 in Review

110 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q4 2024, worth a combined $523M — down 16% from $622M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new ATXS positions and 17 closed out — a net gain of 8 holders — while 42 added to existing stakes and 24 trimmed.

The largest buyer was FCPM III Services, opening a new position worth an estimated $30.5M. The largest seller was VR Adviser, cutting an estimated $10.6M.

  • 110 institutional investors held Astria Therapeutics (ATXS) as of Q4 2024, up from 103 in Q3 2024.
  • Funds reported $523M of Astria Therapeutics stock for Q4 2024, down 16% quarter-over-quarter.
  • 25 funds opened new Astria Therapeutics positions in Q4 2024 and 17 closed out, a net change of +8 holders.
  • The largest Astria Therapeutics buyer in Q4 2024 was FCPM III Services, an estimated $30.5M added.
  • The largest Astria Therapeutics seller in Q4 2024 was VR Adviser, an estimated $10.6M sold.

Based on aggregated 13F filings for Q4 2024.